(19)
(11) EP 4 265 643 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
14.02.2024 Bulletin 2024/07

(43) Date of publication A2:
25.10.2023 Bulletin 2023/43

(21) Application number: 23187271.4

(22) Date of filing: 14.08.2021
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61K 35/17(2015.01)
C07K 16/24(2006.01)
C07K 16/32(2006.01)
C07K 16/42(2006.01)
 A61P 35/00(2006.01)
C12N 5/0783(2010.01)
C07K 16/30(2006.01)
C07K 16/40(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2803; C07K 16/2809; C07K 16/2818; C07K 16/2863; C07K 16/2878; C07K 16/30; C07K 16/32; C07K 16/40; C07K 16/4241; C07K 2317/21; C07K 2317/31; C07K 2317/34; C07K 2317/622; C07K 2317/73; C07K 2317/732; C07K 2317/74; C07K 2317/75; C07K 2317/92
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 14.08.2020 WO PCT/GB2020/051959
17.02.2021 GB 202102222
17.02.2021 GB 202102224

(62) Application number of the earlier application in accordance with Art. 76 EPC:
23153152.6 / 4218932
21756070.5 / 4010082

(71) Applicant: GammaDelta Therapeutics Limited
London W12 7FQ (GB)

(72) Inventors:
  • UDEN, Mark
    London, W12 7FQ (GB)
  • TUNA, Mihriban
    London, W12 7FQ (GB)
  • MOUNT, Natalie
    London, W12 7FQ (GB)
  • GOOD, Robert
    London, W12 7FQ (GB)
  • FREEDMAN, Joshua
    London, W12 7FQ (GB)
  • BHUMBRA, Shefali
    London, W12 7FQ (GB)
  • NUSSBAUMER, Oliver
    London, W12 7FQ (GB)
  • MEHTA, Raj Jaysukhlal
    London, W12 7FQ (GB)

(74) Representative: Heath, Abigail et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)

   


(54) MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES


(57) The present invention relates to multispecific, in particular bispecific, antibodies and fragments and variants thereof that specifically bind the T cell receptor of gamma delta T cells, and one other antigen. More specifically, the present invention provides at least two new classes of bispecific antibodies: bispecific T-cell engagers that bind the variable delta 1 (Vδ1) chain of a γδ T cell receptor (TCR) and a cancer antigen or cancer-associated antigen, and bispecific dual immunomodulators (DIs) that bind the variable delta 1 (Vδ1) chain of a γδ T cell receptor (TCR) and an immunomodulatory antigen.





Search report


















Search report